New combination therapy aims to reduce recurrence in rare lymphoma
NCT ID NCT07450040
Summary
This study is testing whether adding the immunotherapy drug tislelizumab to standard chemotherapy and radiation can better control early-stage NK/T-cell lymphoma and reduce the chance of the cancer coming back. The trial will enroll 60 adults with stage I or II disease who haven't had previous treatment for their lymphoma. Researchers hope this combination approach will be more effective than current treatments while causing fewer side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ORR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
EENT hospital of Fudan University
Shanghai, China, 200000, China
Conditions
Explore the condition pages connected to this study.